The looming spike in costs for those on Obamacare has gotten a lot of attention, but those who get health insurance through their employers are likely to see higher prices, too.
The FDA’s approval of Eli Lilly’s Zepbound could signal more insurers paying for the use of such drugs. Demand is great so the costs could be big and push up premiums.